Haleos Labs Limited (NSE:HALEOSLABS)

Market Cap	3.91B +2.5%
Revenue (ttm)	3.48B +0.6%
Net Income	198.49M -13.9%
EPS	65.65 -13.8%
Shares Out	3.02M
PE Ratio	19.69
Forward PE	n/a
Dividend	1.50 (0.12%)
Ex-Dividend Date	Sep 24, 2025

Volume	502
Average Volume	837
Open	1,291.00
Previous Close	1,292.80
Day's Range	1,290.00 - 1,300.00
52-Week Range	959.80 - 1,680.00
Beta	0.15
RSI	56.29
Earnings Date	Feb 11, 2026

About Haleos Labs

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 592
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: HALEOSLABS

Financial Performance

In fiscal year 2025, Haleos Labs's revenue was 3.45 billion, an increase of 12.67% compared to the previous year's 3.06 billion. Earnings were 201.09 million, an increase of 121.15%.